Semaglutide

The First Modern Breakthrough in Medical Weight Management

PROPeptides Foundations Program

Few medications have transformed the treatment of obesity as dramatically as semaglutide.

Originally developed for the treatment of type 2 diabetes, semaglutide became the first medication to consistently produce average weight reductions approaching those previously seen only after bariatric surgery. Large randomized clinical trials demonstrated that many patients could lose approximately 15% of their body weight while simultaneously improving blood sugar control, blood pressure, lipid profiles, inflammatory markers, liver health, and cardiovascular risk.

These results fundamentally changed how clinicians view obesity treatment. Rather than attempting to overcome hunger through willpower alone, semaglutide works by enhancing one of the body's own natural satiety hormones: glucagon-like peptide-1 (GLP-1).

Importantly, semaglutide is not a stimulant, not an appetite suppressant in the traditional sense, and not a fat-burning medication. Instead, it modifies the biological signals that regulate hunger, fullness, gastric emptying, and glucose metabolism, allowing many patients to naturally consume fewer calories without experiencing the same degree of persistent hunger associated with conventional dieting.

To understand why semaglutide has become one of the most widely prescribed metabolic medications in the world, it is helpful to first understand how it was developed and how it interacts with the body's normal physiology.

From Gila Monster to Modern Medicine

The story of GLP-1 therapy began with an unexpected observation in nature.

Researchers studying the venom of the Gila monster (Heloderma suspectum), a lizard native to the southwestern United States, discovered a peptide called exendin-4. Although structurally different from human GLP-1, exendin-4 activated the same GLP-1 receptor while resisting rapid degradation by the enzyme dipeptidyl peptidase-4 (DPP-4).

This discovery led to the development of exenatide, the first GLP-1 receptor agonist approved for clinical use.

While exenatide demonstrated meaningful improvements in blood glucose and modest weight loss, researchers sought longer-acting molecules that more closely resembled naturally occurring human GLP-1.

Semaglutide represents one of the most successful outcomes of this effort.

Through precise modifications to the amino acid sequence and the addition of a fatty acid side chain that promotes albumin binding, scientists dramatically extended the peptide's half-life from approximately two minutes (native GLP-1) to roughly one week. This allows semaglutide to maintain sustained receptor activation with once-weekly administration.

Rather than replacing natural physiology, semaglutide amplifies one of the body's existing hormonal communication pathways.

What Is Semaglutide?

Semaglutide is a long-acting GLP-1 receptor agonist. It is structurally similar to endogenous GLP-1 but has been engineered to remain in circulation significantly longer.

After subcutaneous injection, semaglutide is slowly absorbed into the bloodstream, binds extensively to albumin, and resists enzymatic degradation. This prolonged circulation enables continuous activation of GLP-1 receptors throughout the week, avoiding the rapid fluctuations seen with naturally secreted GLP-1.

Semaglutide is approved under several brand names and indications, including:

Brand

FDA-Approved Indication

Ozempic®

Type 2 diabetes mellitus

Wegovy®

Chronic weight management

Rybelsus®

Oral treatment of type 2 diabetes

Although the active molecule is the same, dosing schedules and approved indications differ among these products.

How Semaglutide Works

One of semaglutide's greatest strengths is that it does not rely on a single mechanism. Instead, it influences multiple organ systems simultaneously through activation of GLP-1 receptors.

Brain

Perhaps the most clinically important effects occur within the central nervous system.

GLP-1 receptors are present in multiple regions involved in appetite regulation, including the hypothalamus and brainstem. Activation of these pathways reduces hunger, increases satiety after meals, decreases food-related reward signaling, and often reduces intrusive thoughts about eating.

Many patients describe a marked reduction in what has become known as "food noise"—the persistent mental preoccupation with food that can make calorie restriction difficult to sustain.

Rather than forcing individuals to resist hunger, semaglutide often decreases the biological drive to eat.

Stomach

Semaglutide slows gastric emptying, meaning food leaves the stomach more gradually.

This prolongs post-meal fullness and contributes to reduced caloric intake. The slowing of gastric emptying is most pronounced during the early phases of treatment and gradually attenuates over time, although it remains clinically relevant.

This mechanism also contributes to some of the medication's gastrointestinal side effects, particularly nausea during dose escalation.

Pancreas

Semaglutide enhances glucose-dependent insulin secretion.

Importantly, insulin release increases primarily when blood glucose levels are elevated, reducing the risk of hypoglycemia when semaglutide is used alone.

At the same time, semaglutide suppresses inappropriate glucagon secretion during hyperglycemia, improving overall glucose regulation.

Liver

Although semaglutide does not directly act on hepatocytes to reduce glucose production, improvements in insulin sensitivity and reductions in glucagon signaling decrease hepatic glucose output.

Weight loss itself further contributes to improvements in hepatic steatosis, making semaglutide an important therapeutic option for many individuals with metabolic dysfunction-associated steatotic liver disease (MASLD).

Cardiovascular System

Beyond weight loss, semaglutide has demonstrated meaningful cardiovascular benefits.

Large cardiovascular outcome trials have shown reductions in major adverse cardiovascular events among high-risk patients with type 2 diabetes. More recently, the SELECT trial demonstrated cardiovascular benefit even in individuals without diabetes but with obesity and established cardiovascular disease.

These findings suggest that the benefits of semaglutide extend beyond simple weight reduction and likely involve improvements in vascular function, inflammation, insulin resistance, blood pressure, and lipid metabolism.

Clinical Benefits

The effects of semaglutide extend well beyond the number displayed on a scale.

Published clinical trials have demonstrated improvements in:

  • Body weight

  • Waist circumference

  • Visceral adipose tissue

  • Hemoglobin A1c

  • Fasting glucose

  • Insulin resistance

  • Blood pressure

  • Triglycerides

  • Inflammatory markers

  • Fatty liver disease

  • Obstructive sleep apnea severity

  • Mobility and physical function

  • Quality of life

For many patients, these metabolic improvements substantially reduce long-term risks of cardiovascular disease, type 2 diabetes, and other obesity-related complications.

Landmark Clinical Trials

Semaglutide is supported by one of the largest bodies of clinical evidence among weight management medications.

STEP 1 Trial (2021)

The STEP 1 trial enrolled adults with obesity or overweight without diabetes who received semaglutide 2.4 mg weekly alongside lifestyle intervention.

After 68 weeks:

  • Mean weight loss approached 15% of baseline body weight.

  • More than 85% of participants achieved at least 5% weight loss.

  • Approximately half of participants lost 15% or more of their starting weight.

  • A substantial proportion achieved 20% or greater weight reduction, approaching outcomes previously associated primarily with bariatric surgery.

These results established semaglutide as the most effective FDA-approved anti-obesity medication available at the time.

SELECT Trial (2023)

The SELECT trial represented another milestone by evaluating cardiovascular outcomes rather than weight loss alone.

Among adults with overweight or obesity and established cardiovascular disease—but without diabetes—semaglutide significantly reduced:

  • Cardiovascular death

  • Nonfatal myocardial infarction

  • Nonfatal stroke

This trial reinforced the concept that obesity treatment may reduce disease risk beyond improvements in body weight alone.

Who May Benefit?

Semaglutide may be considered for adults who meet evidence-based treatment criteria, including:

  • Body mass index (BMI) ≥30 kg/m², or

  • BMI ≥27 kg/m² with at least one weight-related medical condition such as hypertension, dyslipidemia, obstructive sleep apnea, or prediabetes.

Beyond BMI, clinicians often consider:

  • Waist circumference

  • Visceral adiposity

  • Metabolic health

  • Cardiovascular risk

  • Liver health

  • Functional limitations

  • Previous treatment attempts

  • Patient preferences and goals

Successful treatment requires a comprehensive evaluation rather than reliance on BMI alone.

Looking Ahead

Semaglutide represented the first major breakthrough in modern peptide-based obesity treatment, demonstrating that targeting the GLP-1 receptor alone could produce clinically meaningful and sustained weight loss.

Researchers soon asked an important question:

Could activating more than one metabolic pathway produce even greater results?

This question led directly to the development of tirzepatide, a dual GIP/GLP-1 receptor agonist that further expanded the possibilities of metabolic medicine.

Key References

  1. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.

  2. Rubino DM, et al. STEP Clinical Trial Program. Nature Reviews Endocrinology. 2022.

  3. Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.

  4. Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT Trial). New England Journal of Medicine. 2023.

  5. Drucker DJ. Mechanisms of Action and Therapeutic Applications of GLP-1. Cell Metabolism. 2018.

  6. Nauck MA, Meier JJ. Incretin Physiology and Therapeutic Implications. Diabetologia. 2018.

→ Continue to: Tirzepatide — Dual Incretin Therapy